Researchers might be skeptical and, with people’s lives at stake, that’s understandable. Here’s how to take advantage of the advances while ensuring safeguards are in place.
As artificial intelligence (AI) and machine learning drive innovation and disruption in clinical trials and precision medicine, questions around the responsible use of AI have moved to the forefront of debates among healthcare stakeholders – patients, providers, regulatory authorities, payors and sponsors. To what extent,
Read More
Real World Evidence (RWE)
Aetion Acquires Synthetic Data Platform Replica Analytics
What You Should Know:
- Aetion, a real-world evidence (RWE) tech platform, has just announced its acquisition of Replica Analytics, a pioneer in using ML to generate synthetic data. Financial details of the acquisition were not disclosed.
- This acquisition allows Aetion to solve for one of the toughest problems in RWE: access to fit-for-purpose data. Synthetic data acts as a “digital clone” of real-world data by maintaining the source data’s statistical properties, while also protecting
Read More
Using Real-World Evidence (RWE) & AI to Enable Better Clinical Care
During the prescribing process, a physician’s ability to accurately and reliably match the most appropriate therapy option with the patient at hand is limited by the amount and quality of clinical information that is available. While randomized clinical trials are considered the gold standard for establishing the safety and efficacy of prescription medications, and the clinical findings verified from the trial inform the label on the approved therapy, the overall utility of such trials is
Read More
Bayhealth Taps Syapse’s Real-World Data Platform to Optimize Oncology Data
What You Should Know:
- Syapse, a real-world evidence company that informs cancer care, announced a partnership with Bayhealth – central and southern Delaware’s largest healthcare system.
- Bayhealth will leverage Syapse’ multi-source real-world data platform to bring the latest in cancer diagnostics and treatments to Delaware patients, so that they can receive evidence-based care and match to potentially life-saving clinical trial opportunities.
Bringing Data-Driven Approach to
Read More
Using Machine Learning in the Evolving Landscape of Real-World Data
According to the Food and Drug Administration (FDA), the term real-world data (RWD) refers to routinely collected data relating to patient health status and the delivery of healthcare services, and real-world evidence (RWE) is the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from the analysis of RWD. Both RWD and RWE have increasingly attracted attention in the healthcare industry for years now, and rightly so, considering that the healthcare
Read More
Ontada, Merck Partner to Facilitate Real World Evidence Studies for Cancer Care
What You Should Know:
- Ontada, McKesson’s oncology and insights business, announced a strategic agreement with Merck, known as MSD outside the United States and Canada, that will facilitate the development of real-world research excellence and innovation. This agreement enables the two healthcare leaders to harness the power of real-world evidence (RWE) towards the common goal of improving patient outcomes and the quality of cancer care.
- Ontada and Merck’s combined experience and
Read More
Vivalink Launches RWE Biometrics Data Platform
What You Should Know:
- Vivalink, a provider of digital healthcare solutions for real-world evidence data, announced the launch of its enhanced Biometrics Data Platform to accelerate the development and deployment of patient monitoring and data analysis applications for ambulatory and remote settings. Vivalink’s Biometrics Data Platform completes the company’s end-to-end solution that includes both advanced data services as well as medical wearable sensors.
The Biometrics Data Platform
Read More
U of Chicago Med & COTA to Address Racial Disparities in Cancer Using RWD
What You Should Know:
- COTA, Inc., an oncology real-world data and analytics company and the University of Chicago Medicine announced a research collaboration agreement to investigate racial disparities of care in multiple myeloma to better understand differences in the diagnosis, treatment patterns, and outcomes of patients with this type of cancer.
- Multiple myeloma is the second-most-common hematologic malignancy, with an estimated 34,920 new cases and 12,410 deaths expected to occur
Read More
Aetion Closes $100M to Expand RWE Analytics Platform
What You Should Know:
- Healthcare technology company Aetion announced today a $110M Series C fundraise, led by Warburg Pincus, a leading global growth equity firm, with additional investments from B Capital and Foresite Capital. Aetion’s existing backers New Enterprise Associates (NEA) and Flare Capital Partners also joined the round. Aetion has raised a total of $212M to date.
- The company will use the new funds to extend the capabilities of its Aetion Evidence Platform, expand its
Read More
Carevive, COS Ink Partnership to Improve Cancer Care with RWE
What You Should Know:
- Carevive and Clinical Outcome Solutions (COS) announced a new partnership to improve the cancer patient experience using RWE and RWD. The partnership will leverage Carevive’s innovative digital oncology platform to capture the patient experience, and COS’ deep experience in analyzing data, ultimately providing valuable insights for life science companies and regulators alike.
- The Carevive platform PROmpt enables cancer care teams to monitor and manage
Read More
